Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
AUPH moved a median of +0.13% 30 minutes after news, and -0.17% by the close. How AUPH actually reacts to news — the realized, point-in-time move the market made, measured across 224 labeled events over the last three years with zero look-ahead.
AUPH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 224 |
| 30-min | +0.13% | 54% | 224 |
| 60-min | +0.04% | 50% | 224 |
| to close | -0.17% | 45% | 224 |
| Middle 50% of AUPH reactions | -0.75% to +1.22% |
|---|---|
| Median reaction (30-min) | +0.13% |
| Measured reactions | 224 |
Half of all Aurinia Pharmaceuticals Inc - Common Shares news events land between -0.75% and +1.22% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AUPH reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | -1.67% | 30% | -2.05% |
| Rating reiterations | 19 | -0.09% | 32% | -0.17% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how AUPH ranks against every other measured name →
That’s how AUPH usually reacts — get an email when it moves on news →Email me when AUPH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AUPH's baseline. Nothing else.
Recent AUPH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Aurinia Pharmaceuticals For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -0.24% | -1.41% | |
| Form 8-K Aurinia Pharmaceuticals For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | -0.36% | |
| Aurinia Settles Patent Litigation with Teva | Press release | Business Wire | +3.07% | +4.04% | |
| Form 8-K Aurinia Pharmaceuticals For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | +4.04% | |
| Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress | Press release | Business Wire | -1.17% | +1.25% | |
| Form 10-Q Aurinia Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.17% | +1.25% | |
| Form 8-K Aurinia Pharmaceuticals For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.17% | +1.25% | |
| Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis | Press release | Business Wire | +1.18% | -1.46% | |
| Form 8-K Aurinia Pharmaceuticals For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.40% | -3.77% | |
| LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death | Press release | Business Wire | +1.02% | +4.67% | |
| TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC. | Press release | Canada Newswire | -1.07% | -1.75% | |
| Form 8-K Aurinia Pharmaceuticals For: May 08 | SEC filing · Form 8-K | SEC EDGAR | +2.11% | +3.83% | |
| Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress | Press release | Business Wire | -0.25% | -6.54% | |
| Form 10-Q Aurinia Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.25% | -6.54% | |
| Form 8-K Aurinia Pharmaceuticals For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -6.54% | |
| Form DEF 14A Aurinia Pharmaceuticals For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | +0.13% | +3.08% | |
| Form 8-K Aurinia Pharmaceuticals For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +2.69% | +2.50% | |
| Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right | Press release | Business Wire | -1.26% | -2.24% | |
| Aurinia Announces Management Transition | Press release | Business Wire | +0.85% | +1.11% | |
| Form 8-K Aurinia Pharmaceuticals For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | +1.11% | |
| MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition | Press release | Business Wire | +0.57% | -1.42% | |
| Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress | Press release | Business Wire | -0.98% | -5.93% | |
| Form 10-K Aurinia Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.98% | -5.93% | |
| Form 8-K Aurinia Pharmaceuticals For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | -5.93% | |
| Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 | Press release | Business Wire | -0.63% | +1.20% | |
| Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress | Press release | Business Wire | +12.89% | +5.70% | |
| Form 10-Q Aurinia Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +12.89% | +5.70% | |
| Form 8-K Aurinia Pharmaceuticals For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +12.89% | +5.70% | |
| Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 | Press release | Business Wire | +2.90% | +0.53% | |
| Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 | Press release | Business Wire | +0.62% | +2.05% | |
| Aurinia Responds to Now Retracted LinkedIn Post | Press release | Business Wire | -2.00% | -4.82% | |
| Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 | Press release | Business Wire | +0.69% | -2.17% | |
| Form 10-Q Aurinia Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.69% | -2.17% | |
| Form 8-K Aurinia Pharmaceuticals For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | -2.17% | |
| Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 | Press release | Business Wire | +0.82% | +3.74% | |
| Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) | Press release | Business Wire | +0.00% | -2.31% | |
| Form 8-K Aurinia Pharmaceuticals For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.31% | |
| Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 | Press release | Business Wire | +0.00% | -2.31% | |
| New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis | Press release | Business Wire | +0.96% | -0.60% | |
| Form S-8 Aurinia Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +0.55% | -0.86% | |
| Form 8-K Aurinia Pharmaceuticals For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +0.99% | |
| Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 | Press release | Business Wire | -0.31% | -0.37% | |
| Form 10-Q Aurinia Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.31% | -0.37% | |
| Form 8-K Aurinia Pharmaceuticals For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | -0.37% | |
| Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 | Press release | Business Wire | +0.24% | +0.85% | |
| Form DEFA14A Aurinia Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +0.69% | +2.74% | |
| Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting | Press release | Business Wire | +0.69% | +2.74% | |
| Form DEFA14A Aurinia Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -0.75% | +1.50% | |
| ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting | Press release | Business Wire | -0.75% | +1.50% | |
| Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting | Press release | Business Wire | +0.13% | +0.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AUPH section they belong to.
Where else AUPH is measured.
AUPH earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TETRALOGIC PHARMS CORP (TLOG) | 226 | +0.20% | 52% |
| Y-mAbs Therapeutics, Inc. (YMAB) | 226 | -0.20% | 39% |
| Cel-Sci Corporation (CVM) | 224 | -0.54% | 37% |
| OraSure Technologies, Inc. (OSUR) | 224 | -0.17% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aurinia Pharmaceuticals Inc - Common Shares's median reaction calculated?
Every labeled AUPH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 224 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of AUPH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AUPH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.